Paulo Ferreira

Lisbon, Portugal

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Complete clearance of high-impact sites with risankizumab in patients with psoriasis: a 2-year real-world retrospective multicenter cohort study.

Complete clearance of high-impact sites with risankizumab in patients with psoriasis: a 2-year real-world retrospective multicenter cohort study.

Journal: The Journal of dermatological treatment

Published: May 06, 2026

Risankizumab super responders in moderate-to-severe psoriasis: prevalence, predictors, and long-term maintenance in a multicenter, international, real-world cohort.

Risankizumab super responders in moderate-to-severe psoriasis: prevalence, predictors, and long-term maintenance in a multicenter, international, real-world cohort.

Journal: The Journal of dermatological treatment

Published: January 23, 2026

Real-World Evidence on Dose Spacing of Risankizumab for Psoriasis: A Multicenter Retrospective Cohort Study.

Real-World Evidence on Dose Spacing of Risankizumab for Psoriasis: A Multicenter Retrospective Cohort Study.

Journal: Dermatology and therapy

Published: October 07, 2025

Risankizumab in Patients with Psoriasis with Current or Previous Malignancy: A Multicenter, Retrospective Real-World Study.

Risankizumab in Patients with Psoriasis with Current or Previous Malignancy: A Multicenter, Retrospective Real-World Study.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: September 17, 2025

Real-World Effectiveness, Safety and Drug Survival of Tildrakizumab in Adult Patients With Plaque Psoriasis: A 2-Year Portuguese Multicenter Retrospective Cohort Study.

Real-World Effectiveness, Safety and Drug Survival of Tildrakizumab in Adult Patients With Plaque Psoriasis: A 2-Year Portuguese Multicenter Retrospective Cohort Study.

Journal: International journal of dermatology

Published: June 06, 2025

Real-World Effectiveness, Safety, and Drug Survival of Risankizumab in Adult Patients with Plaque Psoriasis: A 3-Year Multicenter Retrospective Cohort Study.

Real-World Effectiveness, Safety, and Drug Survival of Risankizumab in Adult Patients with Plaque Psoriasis: A 3-Year Multicenter Retrospective Cohort Study.

Journal: American journal of clinical dermatology

Published: May 06, 2025

Real-world experience with brodalumab in a Portuguese cohort of patients with moderate-to-severe psoriasis.

Real-world experience with brodalumab in a Portuguese cohort of patients with moderate-to-severe psoriasis.

Journal: Drugs in context

Published: November 20, 2024

Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort study.

Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: February 02, 2024

Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study.

Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study.

Journal: Drugs in context

Published: December 21, 2023

Epidemiology of Psoriasis in Portugal: A Population-Based Study.

Epidemiology of Psoriasis in Portugal: A Population-Based Study.

Journal: Acta medica portuguesa

Published: September 07, 2022

Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.

Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.

Journal: American journal of clinical dermatology

Published: August 02, 2022

Persistence, effectiveness, and real-world outcomes in psoriasis patients treated with secukinumab in Portugal.

Persistence, effectiveness, and real-world outcomes in psoriasis patients treated with secukinumab in Portugal.

Journal: Dermatologic therapy

Published: February 21, 2022

Showing 1-12 of 22

Last Updated: 09/26/2026